Compare State Street SPDR S&P Biotech ETF (XBI) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Xylem, Inc. — how do they compare? State Street SPDR S&P Biotech ETF trades at $154.43, while Xylem, Inc. trades at $117.66 (market cap $28.67B). The key difference: Xylem, Inc. pays a 1.43% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Xylem, Inc. nearer its low. Which is the better fit depends on your goals.
| XBI | XYL | |
|---|---|---|
Sector | Broad Market / Factor | Industrials |
52-Week High | $164.28 | $152.95 |
52-Week Low | $85.16 | $106.34 |
Market Cap | — | $28.67B |
Enterprise Value | — | $29.92B |
Dividend Yield | — | 1.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XYL trades at $117.00, down 4.71% today, amid mixed technical signals with a bullish overall trend but neutral oscillators. Fundamentally, the company shows steady revenue growth from $8.6B in 2024 to $9.04B in 2025, with net income margins improving to 10.79%. Recent earnings beats and a consistent dividend history support investor confidence, while analyst consensus leans slightly bullish with a $152.71 price target.
The outlook for XYL remains positive given its earnings momentum and strategic partnerships in water technology. Key risks include execution challenges in integrating new leadership and macroeconomic pressures on industrial spending. The stock offers potential upside to analyst targets but requires monitoring of upcoming Q2 2026 results due July 28, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
